These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22196038)

  • 21. Cost-effectiveness of prasugrel in a US managed care population.
    Mauskopf JA; Graham JB; Bae JP; Ramaswamy K; Zagar AJ; Magnuson EA; Cohen DJ; Meadows ES
    J Med Econ; 2012; 15(1):166-74. PubMed ID: 22066985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
    Cui M; Tu CC; Chen EZ; Wang XL; Tan SC; Chen C
    Adv Ther; 2016 Sep; 33(9):1600-11. PubMed ID: 27397588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
    Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance.
    de Groot NL; van Haalen HG; Spiegel BM; Laine L; Lanas A; Focks JJ; Siersema PD; van Oijen MG
    Cardiovasc Drugs Ther; 2013 Aug; 27(4):341-57. PubMed ID: 23417566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results.
    Mantopoulos T; Mitchell PM; Welton NJ; McManus R; Andronis L
    Eur J Health Econ; 2016 Nov; 17(8):927-938. PubMed ID: 26445961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.
    Takabayashi N; Murata K; Tanaka S; Kawakami K
    Pharmacoeconomics; 2015 Oct; 33(10):1091-100. PubMed ID: 25995130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
    Saini SD; Fendrick AM; Scheiman JM
    Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
    Haldemann R; Lüscher TF; Szucs TD
    Praxis (Bern 1994); 2001 Mar; 90(13):539-45. PubMed ID: 11550619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
    J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
    Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
    Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of basiliximab induction in "old-to-old" kidney transplant programs: Bayesian estimation, simulation, and uncertainty analysis.
    Emparan C; Wolters H; Laukötte M; Senninger N
    Transplant Proc; 2005 Jun; 37(5):2069-71. PubMed ID: 15964341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the censored cost-effectiveness analysis using copula information.
    Fontaine C; Daurès JP; Landais P
    BMC Med Res Methodol; 2017 Feb; 17(1):27. PubMed ID: 28202010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
    Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
    Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Impact of the choice of an antiplatelet therapy for peripheral arterial disease: cost-effectiveness ratio and health economics assessment].
    Priollet P; de Pouvourville G
    J Mal Vasc; 2007 Feb; 32(1):8-14. PubMed ID: 17289321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
    Chin CT; Mellstrom C; Chua TS; Matchar DB
    Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.